MARKET

ALKS

ALKS

Alkermes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.22
+0.05
+0.19%
Opening 12:00 06/24 EDT
OPEN
24.13
PREV CLOSE
24.17
HIGH
24.40
LOW
24.10
VOLUME
926.75K
TURNOVER
--
52 WEEK HIGH
25.47
52 WEEK LOW
15.35
MARKET CAP
3.89B
P/E (TTM)
-40.7386
1D
5D
1M
3M
1Y
5Y
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
/PRNewswire/ -- , a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's campaign, which is designed to help raise awareness about the dis...
PR Newswire - PRF · 2d ago
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14)
Benzinga · 06/15 12:07
Stocks That Hit 52-Week Highs On Monday
  During Monday's morning session, 255 companies made new 52-week highs.
Benzinga · 06/14 14:38
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)
Benzinga · 06/11 12:05
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9)
Benzinga · 06/10 12:13
Stocks That Hit 52-Week Highs On Wednesday
    During Wednesday's morning trading, 251 companies set new 52-week highs.
Benzinga · 06/09 14:05
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8)
Benzinga · 06/09 13:14
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALKS. Analyze the recent business situations of Alkermes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALKS stock price target is 22.44 with a high estimate of 29.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 317
Institutional Holdings: 164.09M
% Owned: 102.27%
Shares Outstanding: 160.45M
TypeInstitutionsShares
Increased
63
10.20M
New
27
1.64M
Decreased
65
12.68M
Sold Out
40
2.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.65%
Pharmaceuticals & Medical Research
+1.09%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Pops
Chief Financial Officer/Senior Vice President
Iain Brown
Chief Operating Officer/Executive Vice President
Blair Jackson
Executive Vice President
Craig Hopkinson
Senior Vice President/Chief Compliance Officer/Secretary
David Gaffin
Senior Vice President/Chief Risk Officer
Michael Landine
Senior Vice President
C.Todd Nichols
Lead Director/Independent Director
David Anstice
Director
Shane Cooke
Independent Director
Emily Alva
Independent Director
David Daglio
Independent Director
Wendy Dixon
Independent Director
Richard Gaynor
Independent Director
Brian McKeon
Independent Director
Nancy Snyderman
Independent Director
Frank Wilson
Independent Director
Nancy Wysenski
No Data
  • All
  • Financials
  • Insiders
More
About ALKS
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.